News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
The FDA has approved Moderna’s next-generation COVID-19 vaccine for people older than 65. REUTERS “The FDA approval of our third product, mNEXSPIKE, ...
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results